A Phase 1 Study of LY3023414 in Japanese Patients With Advanced Malignancies

Trial Profile

A Phase 1 Study of LY3023414 in Japanese Patients With Advanced Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs LY 3023414 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 18 Aug 2017 Planned End Date changed from 1 Dec 2018 to 1 Mar 2020.
    • 18 Aug 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top